Alaunos Therapeutics, Inc. (TCRT)
- Previous Close
1.2000 - Open
1.1800 - Bid 1.1500 x 100
- Ask 1.2500 x 100
- Day's Range
1.1700 - 1.3000 - 52 Week Range
0.6000 - 10.5000 - Volume
30,363 - Avg. Volume
93,895 - Market Cap (intraday)
18.895M - Beta (5Y Monthly) -0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-33.0000 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies designed to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen T-cell receptor discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. It has a license agreement with PGEN Therapeutics, Inc.; and research and development agreement with The University of Texas MD Anderson Cancer Center. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
www.alaunos.comRecent News: TCRT
Performance Overview: TCRT
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TCRT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCRT
Valuation Measures
Market Cap
18.89M
Enterprise Value
12.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
251.66
Price/Book (mrq)
3.00
Enterprise Value/Revenue
2.57k
Enterprise Value/EBITDA
-0.42
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.66%
Return on Equity (ttm)
-156.66%
Revenue (ttm)
5k
Net Income Avi to Common (ttm)
-35.14M
Diluted EPS (ttm)
-33.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.06M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.1M